Drugs / MDX-1303
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01204866 | Jul → Aug 2010 | allergic disease | PharmAthene, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00964561 | Aug 2009 → Feb 2010 | anthrax infection | PharmAthene, Inc. | Suspended | No outcome recorded |
| Phase 1 | NCT00964834 | Jul → Oct 2009 | anthrax infection | PharmAthene, Inc. | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01265745 Comparator | Dec 2010 → Aug 2011 | inhalational anthrax | PharmAthene, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDX-1303 | “Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use” NCT01204866 ↗1“Valortim may also be called MDX-1303.” NCT01265745 ↗ |
| Known as | Valortim | “Valortim is the name of the experimental drug that volunteers will receive in this study.” NCT01265745 ↗4“Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use” NCT01204866 ↗ |
| Action | Inhibit | “Valortim binds to PA and interferes with the activity of the toxins.” NCT00964561 ↗ |
| Modality | Monoclonal antibody | “Valortim (MDX-1303) is a fully human monoclonal antibody (hmAb)” NCT00964561 ↗ |
| Route | Intravenous | “Day 4 20mg/kg Valortim IV over 60 minutes.” NCT00964561 ↗ |